SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

27 Jan 2022 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed a Press Release relating to the launch of PrCEQUA™, the first dry eye treatment with nanomicellar technology in Canada, which the company shall be releasing after sending this letter.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma. Inds. Share Price

1868.75 -3.85 (-0.21%)
30-Jun-2026 14:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1868.75
Dr. Reddys Labs. 1365.90
Cipla 1469.70
Zydus Lifesciences 1121.30
Lupin 2432.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: